Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.
Filed under: Ion Channel | Tagged: Adlea, agonist, ALGRX-4975, ALGRX4975, Anesiva, phase II, TRPV1, Vanilloid, VR1 | Leave a Comment »
Anesiva to begin Phase II trial of Capsaicin drug Adlea for use in the treatment of post orthopedic surgery pain.
Filed under: Ion Channel | Tagged: Adlea, agonist, ALGRX-4975, Anesiva, phase II, TRPV1, Vanilloid, VR1 | Leave a Comment »
NeurogesX have submitted an IND for the liquid formulation of Capsaicin, NGX-1998 for the treatment of pain
Filed under: Ion Channel | Tagged: agonist, NeurogesX, Regulatory, TRPV1, Vanilloid, VR1 | Leave a Comment »
